SAN DIEGO, May 28, 2026--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced that the first ...

Cellular immunotherapies have made remarkable progress in the past 10 years and matured into a potent therapeutic modality for combatting cancer. These therapies typically involve harvesting ...

Immune checkpoint therapy has dramatically altered the landscape of cancer treatment, providing notable clinical benefits for some patients, including prolonged survival and persistent responses that ...

A Clinical-Stage Molecule Drives Selective In Vivo Expansion of Tumor-Specific T Cells, Achieving 100% Survival in a High Tumor Burden Ovarian Cancer Model and Promoting Strong Tumor Infiltration in a ...

Combination therapy is essentially a one-two punch at cancer—sometimes with multiple punches. For people with lung cancer, it means treating a tumor with more than one type of therapy at the same time ...

Effects of UCHL1 on tolerogenic DC maturation and promotion of mregDC-Treg crosstalk to nullify anti–PD-L1 therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer. Background: PI3K pathway activation plays a crucial role in mediating ...